AmeriPath, Inc. provides anatomic pathology laboratory and esoteric testing services in the United States. It offers anatomic pathology laboratory testing and information services used by physicians in the detection, diagnosis, evaluation, and treatment of cancer and other medical diseases and conditions. The company provides services in four primary subspecialties of anatomic pathology, which include dermatopathology, women’s health diagnostics, urologic pathology, and gastrointestinal pathology. Its dermatopathology services include physician-to-physician consultation and patient education materials, as well as advanced testing services, such as B-cell and T-cell gene rearrangement, fungal cultures, frozen sections, immunohistochemistry profiles, and indirect and direct immunoflourescence. AmeriPath’s women’s health diagnostic services comprise testing services, such as conventional and monolayer pap smears; cervical and breast biopsy examination; and testing for chlamydia, gonorrhea, and HPV. Its urologic pathology services include examining prostate, bladder, and testicular biopsies; a kidney stone management program; recurrent bladder monitoring for cancer; and prognostic testing, including DNA analysis and tumor markers. The company’s gastrointestinal pathology services comprise microscopic examination of tissues, as well as immunohistochemistry profiles and Microsatellite Instability Testing, an esoteric genetic test for hereditary colorectal cancer. AmeriPath provides its services through 40 outpatient laboratories, as well as inpatient diagnostic and medical director services at approximately 200 hospitals. The company was founded in 1996 and is based in Palm Beach Gardens, Florida. As of May 31, 2007, Ameripath Inc. is a subsidiary of Quest Diagnostics Inc.